Comparing Prostate Biopsy Approaches After MRI in Men With Suspected Prostate Cancer Using Shared Decision Making
Led by Turku University Hospital · Updated on 2021-11-23
600
Participants Needed
4
Research Sites
1043 weeks
Total Duration
AI-Summary
What This Trial Is About
This research focuses on men suspected of having prostate cancer and aims to compare two approaches for deciding when to perform prostate biopsies after MRI scans. The study evaluates whether biopsies guided by shared decision-making based on prostate cancer risk estimation differ in detecting significant cancer compared to biopsies performed routinely after MRI. Researchers seek to improve diagnosis while reducing unnecessary biopsies and have enrolled 600 patients from multiple hospital districts for this randomized trial.
Participants undergo biparametric MRI bpMRI scans interpreted by an experienced urologist using specific scoring systems. Men are randomly assigned to two groups in the control group, all men receive biopsies after MRI in the intervention group, biopsies are done only after a shared decision process considering individual risk. Biopsies involve systematic and targeted samples depending on MRI findings. Men without biopsies or with negative results enter a five-year follow-up with regular PSA tests.
During the study, participants undergo MRI scans, prostate biopsies when indicated, and follow-up PSA testing every six months for five years. Researchers assess the proportion of men with clinically significant prostate cancer Gleason 43 or higher at baseline, biopsy complications, anxiety levels through questionnaires, and biopsy rates. Long-term follow-up continues for 15 years using health records and registries to monitor outcomes beyond the initial study period.
CONDITIONS
Brief Title
bpMRI and Risk Based Shared Clinical Decision Making in Prostate Cancer Diagnosis
Research Team
P
Peter Boström, MD
O
Otto Ettala, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Suspicion of prostate cancer based on PSA level from 2.5 to 20 ng/ml and/or abnormal digital rectal exam
Able to understand the study and give informed consent
Signed approved informed consent documents
You will not qualify if you...
Previous diagnosis of prostate cancer
Contraindications for MRI
Any condition compromising patient safety as judged by urologist
Presence of bilateral hip prosthesis
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Diagnostic Evaluation
Duration - Baseline
Participants undergo a pre-biopsy biparametric MRI scan to assess prostate cancer risk.
1 visit (in-person)
Treatment
Duration - Baseline
Participants either undergo prostate biopsies after MRI or participate in shared decision-making to determine biopsy necessity based on risk estimation.
1 visit (in-person)
Long-term Monitoring
Duration - 5 years with additional 15 years of registry follow-up
Participants with negative biopsies or no biopsies performed are followed with semi-annual PSA tests for five years and additional long-term follow-up through health records and national registries.
Semi-annual visits for PSA testing during first 5 years
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
DIAGNOSTIC
Number of Arms
2
Similar Trials
Study of 177Lu-PSMA as an Additional Treatment for High and Very High Risk Prostate Cancer After Radiation and Hormone Therapy
Phase 1b Study of 177Lu-PSMA-617 With Liver-Directed Therapy for Metastatic Castration-Resistant Prostate Cancer
Using 18F-PSMA-1007 PET-CT to Guide Targeted Focal Therapy for MRI-Invisible Prostate Cancer
A Prospective Phase II Study Evaluating PET-Directed Treatment in Men with Localized Intermediate-Risk Prostate Cancer
Evaluation of 18F-PSMA-1007 PETCT Imaging Safety and Effectiveness in Adult Men with Prostate Cancer
Combining One MR-Guided HDR Brachytherapy and One SABR Treatment
for Favorable Risk Prostate Cancer
in a Phase 23 Study
Study of 4-Aminopyridine to Improve Nerve Recovery After Robot-Assisted Radical Prostatectomy in Men with Prostate Cancer
Phase III Study of 64Cu-GRIP B PET Imaging for Detecting Granzyme B in Adults with Advanced Genitourinary and Other Solid Tumors
Comparison of 68Ga-P16-093 and 68Ga-PSMA-11 PETCT Scans for Detecting Primary Prostate Cancer in Men
Using 68Ga-PSMA PETMRI and mpMRI to Detect Prostate Cancer in Men Aged 40 to 85
Observational Study to Compare Diagnostic Accuracy and Follow-Up Outcomes
PETCT Imaging Using 68Ga-RM26-RGD to Detect Breast, Brain, and Prostate Tumors with GRPR and v3 Receptors
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Individualised non-contrast MRI-based risk estimation and shared decision-making in men with a suspicion of prostate cancer: protocol for multicentre randomised controlled trial (multi-IMPROD V.2.0).